The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Biologics and Biosimilars Market Research Report 2025

Global Biologics and Biosimilars Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1410783

No of Pages : 103

Ask Your Query

Synopsis
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

The global Biologics and Biosimilars market was valued at US$ 468270 million in 2023 and is anticipated to reach US$ 674510 million by 2030, witnessing a CAGR of 8.7% during the forecast period 2024-2030.

Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.

This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.
Report Scope

The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biologics and Biosimilars companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

  • Roche
  • Amgen
  • AbbVie
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • Biogen
  • Celltrion
  • Sobi
  • 3SBIO
  • Changchun High Tech
  • Kanghong Pharma
  • Innovent Biologics
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory

Segment by Type

  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Others

Segment by Application

  • Hospital
  • Retail Pharmacy
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biologics and Biosimilars Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Biologics and Biosimilars Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biologics and Biosimilars Market Perspective (2019-2030)
2.2 Biologics and Biosimilars Growth Trends by Region
2.2.1 Global Biologics and Biosimilars Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biologics and Biosimilars Historic Market Size by Region (2019-2024)
2.2.3 Biologics and Biosimilars Forecasted Market Size by Region (2025-2030)
2.3 Biologics and Biosimilars Market Dynamics
2.3.1 Biologics and Biosimilars Industry Trends
2.3.2 Biologics and Biosimilars Market Drivers
2.3.3 Biologics and Biosimilars Market Challenges
2.3.4 Biologics and Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biologics and Biosimilars Players by Revenue
3.1.1 Global Top Biologics and Biosimilars Players by Revenue (2019-2024)
3.1.2 Global Biologics and Biosimilars Revenue Market Share by Players (2019-2024)
3.2 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biologics and Biosimilars Revenue
3.4 Global Biologics and Biosimilars Market Concentration Ratio
3.4.1 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologics and Biosimilars Revenue in 2023
3.5 Biologics and Biosimilars Key Players Head office and Area Served
3.6 Key Players Biologics and Biosimilars Product Solution and Service
3.7 Date of Enter into Biologics and Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologics and Biosimilars Breakdown Data by Type
4.1 Global Biologics and Biosimilars Historic Market Size by Type (2019-2024)
4.2 Global Biologics and Biosimilars Forecasted Market Size by Type (2025-2030)
5 Biologics and Biosimilars Breakdown Data by Application
5.1 Global Biologics and Biosimilars Historic Market Size by Application (2019-2024)
5.2 Global Biologics and Biosimilars Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biologics and Biosimilars Market Size (2019-2030)
6.2 North America Biologics and Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biologics and Biosimilars Market Size by Country (2019-2024)
6.4 North America Biologics and Biosimilars Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biologics and Biosimilars Market Size (2019-2030)
7.2 Europe Biologics and Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biologics and Biosimilars Market Size by Country (2019-2024)
7.4 Europe Biologics and Biosimilars Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biologics and Biosimilars Market Size (2019-2030)
8.2 Asia-Pacific Biologics and Biosimilars Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biologics and Biosimilars Market Size by Region (2019-2024)
8.4 Asia-Pacific Biologics and Biosimilars Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biologics and Biosimilars Market Size (2019-2030)
9.2 Latin America Biologics and Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biologics and Biosimilars Market Size by Country (2019-2024)
9.4 Latin America Biologics and Biosimilars Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biologics and Biosimilars Market Size (2019-2030)
10.2 Middle East & Africa Biologics and Biosimilars Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biologics and Biosimilars Market Size by Country (2019-2024)
10.4 Middle East & Africa Biologics and Biosimilars Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Biologics and Biosimilars Introduction
11.1.4 Roche Revenue in Biologics and Biosimilars Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Biologics and Biosimilars Introduction
11.2.4 Amgen Revenue in Biologics and Biosimilars Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Biologics and Biosimilars Introduction
11.3.4 AbbVie Revenue in Biologics and Biosimilars Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biologics and Biosimilars Introduction
11.4.4 Sanofi Revenue in Biologics and Biosimilars Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Biologics and Biosimilars Introduction
11.5.4 Johnson & Johnson Revenue in Biologics and Biosimilars Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Biologics and Biosimilars Introduction
11.6.4 Pfizer Revenue in Biologics and Biosimilars Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Detail
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Biologics and Biosimilars Introduction
11.7.4 Novo Nordisk Revenue in Biologics and Biosimilars Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Detail
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Biologics and Biosimilars Introduction
11.8.4 Eli Lilly Revenue in Biologics and Biosimilars Business (2019-2024)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Biologics and Biosimilars Introduction
11.9.4 Novartis Revenue in Biologics and Biosimilars Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Biologics and Biosimilars Introduction
11.10.4 Merck Revenue in Biologics and Biosimilars Business (2019-2024)
11.10.5 Merck Recent Development
11.11 Biogen
11.11.1 Biogen Company Detail
11.11.2 Biogen Business Overview
11.11.3 Biogen Biologics and Biosimilars Introduction
11.11.4 Biogen Revenue in Biologics and Biosimilars Business (2019-2024)
11.11.5 Biogen Recent Development
11.12 Celltrion
11.12.1 Celltrion Company Detail
11.12.2 Celltrion Business Overview
11.12.3 Celltrion Biologics and Biosimilars Introduction
11.12.4 Celltrion Revenue in Biologics and Biosimilars Business (2019-2024)
11.12.5 Celltrion Recent Development
11.13 Sobi
11.13.1 Sobi Company Detail
11.13.2 Sobi Business Overview
11.13.3 Sobi Biologics and Biosimilars Introduction
11.13.4 Sobi Revenue in Biologics and Biosimilars Business (2019-2024)
11.13.5 Sobi Recent Development
11.14 3SBIO
11.14.1 3SBIO Company Detail
11.14.2 3SBIO Business Overview
11.14.3 3SBIO Biologics and Biosimilars Introduction
11.14.4 3SBIO Revenue in Biologics and Biosimilars Business (2019-2024)
11.14.5 3SBIO Recent Development
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Detail
11.15.2 Changchun High Tech Business Overview
11.15.3 Changchun High Tech Biologics and Biosimilars Introduction
11.15.4 Changchun High Tech Revenue in Biologics and Biosimilars Business (2019-2024)
11.15.5 Changchun High Tech Recent Development
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Detail
11.16.2 Kanghong Pharma Business Overview
11.16.3 Kanghong Pharma Biologics and Biosimilars Introduction
11.16.4 Kanghong Pharma Revenue in Biologics and Biosimilars Business (2019-2024)
11.16.5 Kanghong Pharma Recent Development
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Detail
11.17.2 Innovent Biologics Business Overview
11.17.3 Innovent Biologics Biologics and Biosimilars Introduction
11.17.4 Innovent Biologics Revenue in Biologics and Biosimilars Business (2019-2024)
11.17.5 Innovent Biologics Recent Development
11.18 Gan&Lee
11.18.1 Gan&Lee Company Detail
11.18.2 Gan&Lee Business Overview
11.18.3 Gan&Lee Biologics and Biosimilars Introduction
11.18.4 Gan&Lee Revenue in Biologics and Biosimilars Business (2019-2024)
11.18.5 Gan&Lee Recent Development
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Detail
11.19.2 Tonghua Dongbao Business Overview
11.19.3 Tonghua Dongbao Biologics and Biosimilars Introduction
11.19.4 Tonghua Dongbao Revenue in Biologics and Biosimilars Business (2019-2024)
11.19.5 Tonghua Dongbao Recent Development
11.20 United Laboratory
11.20.1 United Laboratory Company Detail
11.20.2 United Laboratory Business Overview
11.20.3 United Laboratory Biologics and Biosimilars Introduction
11.20.4 United Laboratory Revenue in Biologics and Biosimilars Business (2019-2024)
11.20.5 United Laboratory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock